<p>BTC Capital Management Inc. 在最近向证券交易委员会的披露中表示，在第二季度将其在安进公司（NASDAQ:AMGN - 免费报告）的股份增加了 20.5%。该公司在本季度购买了 1,367 股后，持有 8,039 股这家医疗研究公司的股票。BTC Capital Management Inc. 在安进的持股在最近一个季度末价值为 2,214,000 美元。</p>
<ul>
<li>3 家生物技术巨头受益于美国销售和政策变化</li>
</ul>
<p>其他几家对冲基金最近也调整了对 AMGN 的持股。财富保护顾问公司在第一季度获得了价值 25,000 美元的安进新股份。第一太平洋金融在第一季度将其在安进的股份增加了 304.5%。第一太平洋金融现在拥有 89 股这家医疗研究公司的股票，价值 28,000 美元，此前在上个季度又购买了 67 股。CBIZ 投资顾问服务公司在第一季度将其在安进的股份增加了 1,214.3%。CBIZ 投资顾问服务公司现在拥有 92 股这家医疗研究公司的股票，价值 29,000 美元，此前在上个季度又购买了 85 股。Pinney &amp; Scofield Inc. 在第四季度获得了价值约 26,000 美元的安进新股份。最后，Activest Wealth Management 在第一季度将其在安进的持股增加了 3,433.3%。Activest Wealth Management 现在拥有 106 股这家医疗研究公司的股票，价值 33,000 美元，此前在上个季度又购买了 103 股。76.50% 的股票由机构投资者持有。</p>
<h2>华尔街分析师预测增长</h2>
<p>AMGN 已经成为几份分析师报告的主题。雷蒙德·詹姆斯金融在 9 月 3 日星期三的研究报告中开始覆盖安进的股票。他们对该公司的评级为 “市场表现”。Cantor Fitzgerald 在 6 月 24 日星期二的研究报告中重申了 “中性” 评级，并设定了 305.00 美元的目标价。花旗集团在 8 月 6 日星期三的研究报告中将安进的目标价从 305.00 美元上调至 310.00 美元，并给予该公司 “中性” 评级。瑞银集团在 8 月 6 日星期三的研究报告中将安进的目标价从 326.00 美元下调至 317.00 美元，并对该股票设定了 “中性” 评级。最后，美国银行在 7 月 23 日星期三的研究报告中将安进的目标价从 252.00 美元上调至 261.00 美元，并给予该股票 “表现不佳” 的评级。七位研究分析师对该股票给予了买入评级，十二位给予了持有评级，两位给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “持有”，平均目标价为 304.43 美元。</p>
<ul>
<li>MarketBeat 周回顾 – 12/2 - 12/6</li>
</ul>
<p><strong>获取我们关于 AMGN 的最新研究报告</strong></p>
<h2>安进股票上涨 3.5%</h2>
<p>NASDAQ AMGN 在周五开盘价为 285.41 美元。该公司的债务与股本比率为 7.24，速动比率为 0.98，流动比率为 1.31。该公司的市值为 1536.5 亿美元，市盈率为 23.34，市盈增长比率为 2.48，贝塔值为 0.49。安进公司的一年低点为 253.30 美元，一年高点为 339.17 美元。该股票的 50 日移动平均价格为 290.57 美元，200 日移动平均价格为 290.48 美元。</p>
<ul>
<li>安进股票因减肥药数据下跌：反应过度还是合理？</li>
</ul>
<p>安进（NASDAQ:AMGN - 获取免费报告）在 8 月 5 日星期二发布了季度财报。这家医疗研究公司报告的每股收益为 6.02 美元，超出市场共识预期的 5.28 美元，超出 0.74 美元。安进的净利润率为 18.96%，股本回报率为 174.71%。该公司在本季度的收入为 91.8 亿美元，而分析师预期为 88.6 亿美元。在去年同期，该公司每股收益为 4.97 美元。安进的季度收入同比增长 9.4%。安进已将其 2025 财年的指导目标设定为 20.200-21.300 每股收益。作为一个整体，股票分析师预测安进公司在当前财年将发布 20.62 每股收益。</p>
<h2>安进分红公告</h2>
<p>该公司最近还宣布了季度分红，已于 9 月 12 日星期五支付。8 月 22 日星期五的登记投资者获得了 2.38 美元的分红。这代表着每年 9.52 美元的分红和 3.3% 的收益率。除息日期为 8 月 22 日星期五。安进的分红支付比率为 77.84%。</p>
<h2>安进内部交易</h2>
<p>在其他新闻中，高级副总裁南希·A·格里吉尔在 8 月 20 日星期三的交易中出售了 1,267 股公司的股票。该股票以 296.99 美元的平均价格出售，总价值为 376,286.33 美元。交易完成后，该高级副总裁直接持有公司 7,209 股，价值为 2,141,000.91 美元。此次交易使其持股减少了 14.95%。该交易已在向证券交易委员会的备案中披露，相关文件可通过此链接获取。内部人士持有公司 0.76% 的股票。</p>
<h2>安进公司简介</h2>
<p>（免费报告）</p>
<p>安进公司在全球范围内发现、开发、生产和交付人用治疗药物。该公司的主要产品包括用于治疗斑块型银屑病、类风湿性关节炎和银屑病关节炎的恩利昔（Enbrel）；用于治疗成人斑块型银屑病、银屑病关节炎和与贝赫切特病相关的口腔溃疡的奥特兹拉（Otezla）；用于治疗绝经后女性骨质疏松症的普利亚（Prolia）；用于预防骨骼相关事件的 XGEVA；可减少心肌梗死、中风和冠状动脉再血管化风险的 Repatha；用于治疗免疫性血小板减少症患者的 Nplate；用于治疗复发性或难治性多发性骨髓瘤患者的 KYPROLIS；用于治疗红细胞数量低于正常水平和贫血的 Aranesp；用于治疗绝经后男性和女性骨质疏松症的 EVENITY；用于治疗野生型 RAS 转移性结直肠癌患者的 Vectibix；用于治疗急性淋巴细胞白血病患者的 BLINCYTO；用于治疗甲状腺眼病的 TEPEZZA；以及用于治疗慢性难治性痛风的 KRYSTEXXA。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票超过安进</li>
<li>5 个适合股息增长投资者的折扣机会</li>
<li>卡特彼勒股票创下历史新高——还有更多上涨空间吗？</li>
<li>什么是微型股？你需要知道的一切</li>
<li>伯克希尔支持的 Lennar 在疲软的第三季度财报后下滑</li>
<li>什么是日经 225 指数？</li>
<li>分析师对好时（Hershey）转为看涨——百事可乐是下一个价值投资吗？</li>
</ul>
<p><strong>想看看其他对 AMGN 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com，获取安进公司（NASDAQ:AMGN - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在安进吗？</h2>
<p>在考虑安进之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而安进并不在名单上。</p>
<p>虽然安进目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

安进

<p>BTC Capital Management Inc. 在第二季度将其在安进（Amgen Inc.）的持股增加了 20.5%，额外购买了 1,367 股，总持股达到 8,039 股，价值 221 万美元。其他对冲基金也调整了在安进的持股。分析师对该股票的评级意见不一，普遍评级为 “持有”，平均目标价为 304.43 美元。安进报告了强劲的季度收益，超出预期，并宣布季度股息为 2.38 美元，收益率为 3.3%</p>

<p>BTC Capital Management Inc. boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 20.5% in the second quarter, according to its most recent disclosure with the Securities &amp; Exchange Commission. The firm owned 8,039 shares of the medical research company's stock after purchasing an additional 1,367 shares during the quarter. BTC Capital Management Inc.'s holdings in Amgen were worth $2,214,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>BTC Capital Management Inc. 在最近向证券交易委员会的披露中表示，在第二季度将其在安进公司（NASDAQ:AMGN - 免费报告）的股份增加了 20.5%。该公司在本季度购买了 1,367 股后，持有 8,039 股这家医疗研究公司的股票。BTC Capital Management Inc. 在安进的持股在最近一个季度末价值为 2,214,000 美元。</p>
</div><ul>
<li>3 Biotech Giants Gaining From U.S. Sales and Policy Shifts</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家生物技术巨头受益于美国销售和政策变化</li>
</ul>
</div><p>Several other hedge funds also recently modified their holdings of AMGN. Wealth Preservation Advisors LLC acquired a new stake in shares of Amgen in the first quarter valued at $25,000. First Pacific Financial lifted its stake in Amgen by 304.5% in the 1st quarter. First Pacific Financial now owns 89 shares of the medical research company's stock valued at $28,000 after acquiring an additional 67 shares in the last quarter. CBIZ Investment Advisory Services LLC increased its position in shares of Amgen by 1,214.3% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 92 shares of the medical research company's stock worth $29,000 after purchasing an additional 85 shares during the last quarter. Pinney &amp; Scofield Inc. acquired a new position in shares of Amgen during the 4th quarter worth approximately $26,000. Finally, Activest Wealth Management increased its holdings in shares of Amgen by 3,433.3% during the 1st quarter. Activest Wealth Management now owns 106 shares of the medical research company's stock worth $33,000 after acquiring an additional 103 shares during the last quarter. 76.50% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他几家对冲基金最近也调整了对 AMGN 的持股。财富保护顾问公司在第一季度获得了价值 25,000 美元的安进新股份。第一太平洋金融在第一季度将其在安进的股份增加了 304.5%。第一太平洋金融现在拥有 89 股这家医疗研究公司的股票，价值 28,000 美元，此前在上个季度又购买了 67 股。CBIZ 投资顾问服务公司在第一季度将其在安进的股份增加了 1,214.3%。CBIZ 投资顾问服务公司现在拥有 92 股这家医疗研究公司的股票，价值 29,000 美元，此前在上个季度又购买了 85 股。Pinney &amp; Scofield Inc. 在第四季度获得了价值约 26,000 美元的安进新股份。最后，Activest Wealth Management 在第一季度将其在安进的持股增加了 3,433.3%。Activest Wealth Management 现在拥有 106 股这家医疗研究公司的股票，价值 33,000 美元，此前在上个季度又购买了 103 股。76.50% 的股票由机构投资者持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>AMGN has been the subject of several analyst reports. Raymond James Financial initiated coverage on shares of Amgen in a research report on Wednesday, September 3rd. They issued a &#34;market perform&#34; rating for the company. Cantor Fitzgerald reissued a &#34;neutral&#34; rating and set a $305.00 target price on shares of Amgen in a research note on Tuesday, June 24th. Citigroup raised their price objective on shares of Amgen from $305.00 to $310.00 and gave the company a &#34;neutral&#34; rating in a research note on Wednesday, August 6th. UBS Group lowered their price objective on shares of Amgen from $326.00 to $317.00 and set a &#34;neutral&#34; rating on the stock in a research report on Wednesday, August 6th. Finally, Bank of America lifted their target price on shares of Amgen from $252.00 to $261.00 and gave the stock an &#34;underperform&#34; rating in a research note on Wednesday, July 23rd. Seven research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of &#34;Hold&#34; and an average target price of $304.43.</p>
<div class="lb-trans"><p>AMGN 已经成为几份分析师报告的主题。雷蒙德·詹姆斯金融在 9 月 3 日星期三的研究报告中开始覆盖安进的股票。他们对该公司的评级为 “市场表现”。Cantor Fitzgerald 在 6 月 24 日星期二的研究报告中重申了 “中性” 评级，并设定了 305.00 美元的目标价。花旗集团在 8 月 6 日星期三的研究报告中将安进的目标价从 305.00 美元上调至 310.00 美元，并给予该公司 “中性” 评级。瑞银集团在 8 月 6 日星期三的研究报告中将安进的目标价从 326.00 美元下调至 317.00 美元，并对该股票设定了 “中性” 评级。最后，美国银行在 7 月 23 日星期三的研究报告中将安进的目标价从 252.00 美元上调至 261.00 美元，并给予该股票 “表现不佳” 的评级。七位研究分析师对该股票给予了买入评级，十二位给予了持有评级，两位给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “持有”，平均目标价为 304.43 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 12/2 - 12/6</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 12/2 - 12/6</li>
</ul>
</div><p><strong>Get Our Latest Research Report on AMGN</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 AMGN 的最新研究报告</strong></p>
</div><h2>Amgen Stock Up 3.5%</h2>
<div class="lb-trans"><h2>安进股票上涨 3.5%</h2>
</div><p>NASDAQ AMGN opened at $285.41 on Friday. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31. The company has a market capitalization of $153.65 billion, a P/E ratio of 23.34, a P/E/G ratio of 2.48 and a beta of 0.49. Amgen Inc. has a one year low of $253.30 and a one year high of $339.17. The stock has a 50 day moving average price of $290.57 and a 200-day moving average price of $290.48.</p>
<div class="lb-trans"><p>NASDAQ AMGN 在周五开盘价为 285.41 美元。该公司的债务与股本比率为 7.24，速动比率为 0.98，流动比率为 1.31。该公司的市值为 1536.5 亿美元，市盈率为 23.34，市盈增长比率为 2.48，贝塔值为 0.49。安进公司的一年低点为 253.30 美元，一年高点为 339.17 美元。该股票的 50 日移动平均价格为 290.57 美元，200 日移动平均价格为 290.48 美元。</p>
</div><ul>
<li>Amgen Stock Falls on Weight Loss Drug Data: Overreaction or Fair?</li>
</ul>
<div class="lb-trans"><ul>
<li>安进股票因减肥药数据下跌：反应过度还是合理？</li>
</ul>
</div><p>Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The medical research company reported $6.02 EPS for the quarter, topping the consensus estimate of $5.28 by $0.74. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The company had revenue of $9.18 billion during the quarter, compared to analyst estimates of $8.86 billion. During the same period in the previous year, the firm earned $4.97 earnings per share. Amgen's quarterly revenue was up 9.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. As a group, equities analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>安进（NASDAQ:AMGN - 获取免费报告）在 8 月 5 日星期二发布了季度财报。这家医疗研究公司报告的每股收益为 6.02 美元，超出市场共识预期的 5.28 美元，超出 0.74 美元。安进的净利润率为 18.96%，股本回报率为 174.71%。该公司在本季度的收入为 91.8 亿美元，而分析师预期为 88.6 亿美元。在去年同期，该公司每股收益为 4.97 美元。安进的季度收入同比增长 9.4%。安进已将其 2025 财年的指导目标设定为 20.200-21.300 每股收益。作为一个整体，股票分析师预测安进公司在当前财年将发布 20.62 每股收益。</p>
</div><h2>Amgen Dividend Announcement</h2>
<div class="lb-trans"><h2>安进分红公告</h2>
</div><p>The firm also recently declared a quarterly dividend, which was paid on Friday, September 12th. Investors of record on Friday, August 22nd were issued a $2.38 dividend. This represents a $9.52 annualized dividend and a yield of 3.3%. The ex-dividend date was Friday, August 22nd. Amgen's dividend payout ratio is 77.84%.</p>
<div class="lb-trans"><p>该公司最近还宣布了季度分红，已于 9 月 12 日星期五支付。8 月 22 日星期五的登记投资者获得了 2.38 美元的分红。这代表着每年 9.52 美元的分红和 3.3% 的收益率。除息日期为 8 月 22 日星期五。安进的分红支付比率为 77.84%。</p>
</div><h2>Insider Transactions at Amgen</h2>
<div class="lb-trans"><h2>安进内部交易</h2>
</div><p>In other news, SVP Nancy A. Grygiel sold 1,267 shares of the business's stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total value of $376,286.33. Following the completion of the sale, the senior vice president directly owned 7,209 shares in the company, valued at $2,141,000.91. The trade was a 14.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this link. Insiders own 0.76% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，高级副总裁南希·A·格里吉尔在 8 月 20 日星期三的交易中出售了 1,267 股公司的股票。该股票以 296.99 美元的平均价格出售，总价值为 376,286.33 美元。交易完成后，该高级副总裁直接持有公司 7,209 股，价值为 2,141,000.91 美元。此次交易使其持股减少了 14.95%。该交易已在向证券交易委员会的备案中披露，相关文件可通过此链接获取。内部人士持有公司 0.76% 的股票。</p>
</div><h2>Amgen Profile</h2>
<div class="lb-trans"><h2>安进公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.</p>
<div class="lb-trans"><p>安进公司在全球范围内发现、开发、生产和交付人用治疗药物。该公司的主要产品包括用于治疗斑块型银屑病、类风湿性关节炎和银屑病关节炎的恩利昔（Enbrel）；用于治疗成人斑块型银屑病、银屑病关节炎和与贝赫切特病相关的口腔溃疡的奥特兹拉（Otezla）；用于治疗绝经后女性骨质疏松症的普利亚（Prolia）；用于预防骨骼相关事件的 XGEVA；可减少心肌梗死、中风和冠状动脉再血管化风险的 Repatha；用于治疗免疫性血小板减少症患者的 Nplate；用于治疗复发性或难治性多发性骨髓瘤患者的 KYPROLIS；用于治疗红细胞数量低于正常水平和贫血的 Aranesp；用于治疗绝经后男性和女性骨质疏松症的 EVENITY；用于治疗野生型 RAS 转移性结直肠癌患者的 Vectibix；用于治疗急性淋巴细胞白血病患者的 BLINCYTO；用于治疗甲状腺眼病的 TEPEZZA；以及用于治疗慢性难治性痛风的 KRYSTEXXA。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Amgen</li>
<li>5 discounted opportunities for dividend growth investors</li>
<li>Caterpillar Stock Hits All-Time High—Is There More Room to Run?</li>
<li>What is a Microcap Stock? Everything You Need to Know</li>
<li>Berkshire-Backed Lennar Slides After Weak Q3 Earnings</li>
<li>What is the Nikkei 225 index?</li>
<li>Analysts Turn Bullish on Hershey—Is Pepsi the Next Value Play?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过安进</li>
<li>5 个适合股息增长投资者的折扣机会</li>
<li>卡特彼勒股票创下历史新高——还有更多上涨空间吗？</li>
<li>什么是微型股？你需要知道的一切</li>
<li>伯克希尔支持的 Lennar 在疲软的第三季度财报后下滑</li>
<li>什么是日经 225 指数？</li>
<li>分析师对好时（Hershey）转为看涨——百事可乐是下一个价值投资吗？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding AMGN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 AMGN 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com，获取安进公司（NASDAQ:AMGN - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AMGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Amgen Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在安进吗？</h2>
</div><p>Before you consider Amgen, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑安进之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而安进并不在名单上。</p>
</div><p>While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然安进目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

BTC 资本管理公司购入了安进公司 1,367 股股票